GSK agreed to pay $110 million for a Phase 1-ready Hutchmed asset in a new class of cancer drugs based on antibody-targeted therapy conjugates (ATTCs). The deal gives GSK rights to the first asset, which is designed to block two cancer-driving proteins and will initially be developed for lung, colorectal, and pancreatic cancers. The payment structure signals GSK’s intent to accelerate access to next-generation targeted conjugate formats while leveraging Hutchmed’s oncology pipeline development. For the ATTC concept, the key will be early clinical tolerability and whether dual-target blockade produces meaningful antitumor activity across these solid tumor types. The acquisition also highlights how large pharma continues to buy in to platform innovation rather than building all conjugate IP internally, potentially reshaping timelines for oncology next-gen modalities.